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treatment with either latanoprost or travoprost. A Bayesian
network was constructed to study the association between
daytime IOP and nocturnal IOP and treatment effects, adjusted
for trial effects. RESULTS: A total of 382 daily IOP vectors were
identiﬁed (pre-treatment: 208; latanoprost: 73; travoprost: 101).
IOP at 08:00h was associated with IOP at 12:00h, which was
associated with IOP at 16:00h. IOP at 20:00h was predicted by
IOPs at 12:00h and 16:00h. The predicted nocturnal peak IOP
was associated with IOPs at 12:00h and 20:00h. Travoprost con-
trolled the latter IOPs (12:00h and 20:00h) better than
latanoprost, increasing the probability of controlling nocturnal
IOP peaks °Y´ 18 mmHg (travoprost 76.9–77.5% versus
latanoprost 66.7–67.9%). Untreated patients with a diagnosis of
ocular hypertension had a high probability of developing a noc-
turnal IOP peak °Y´ 18 mmHg (92.1%). CONCLUSIONS:
Daytime IOP measurements are highly intercorrelated. IOPs at
12:00h and 20:00h were associated with the nocturnal IOP peak.
Bayesian networks can estimate the risk of a night time IOP peak
°Y´ 18 mmHg. Daytime IOP control is important for nocturnal
IOP control.
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OBJECTIVE: To compare the effectiveness of travoprost 
(Travatan®) and a dorzolamide+timolol ﬁxed combination
(Cosopt®) as alternative ﬁrst line therapies for glaucoma using
data from the UK General Practitioner Research Database (UK-
GPRD). METHODS: Files of patients with ocular hypertension
or glaucoma, treated topically, or by surgery or laser therapy,
were extracted from the UK-GPRD. Patients starting ﬁrst line
treatment with travoprost, or the ﬁxed dorzolamide+timolol
combination, were selected. Treatment failure was deﬁned as a
prescription change (adding or removing a topical treatment).
Time to treatment failure was compared between treatments by
an adjusted Cox model. Propensity scores were used. RESULTS:
Files on 56,612 patients were extracted of which 39,808 had at
least one topical prescription for glaucoma. In total, 639 patients
were treated with travoprost, and 387 with dorzolamide+
timolol, as ﬁrst line therapies. Demographic and health charac-
teristics did not differ signiﬁcantly between patient groups.
Overall mean age at diagnosis was 70.0 years and 48.5% were
male. Treatment failure at one year occurred in 30.4% of
patients on travoprost and by 49.4% on dorzolamide+timolol (p
< 0.001). The hazard ratio for failure was lower with travoprost
(0.79: p < 0.03) after adjusting for age, gender, comorbidities and
duration of follow-up. CONCLUSION: According to UK-GPRD
information, travoprost appears to be more efﬁcient than dor-
zolamide+timolol as ﬁrst line therapy for glaucoma patients.
Patients continue longer with travoprost as ﬁrst line therapy.
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OBJECTIVE: To compare the efﬁcacy of latanoprost, bimato-
prost and travoprost for controlling IOP. METHODS: Ran-
domized trials were identiﬁed on Medline and Embase using the
following key words: glaucoma, ocular hypertension (OHT),
randomization, trial, latanoprost, bimatoprost and travoprost.
The studies had to compare at least two prostaglandins in
monotherapy. Cross-over experimental designs were excluded.
IOP at baseline and ﬁnal visit, age, gender, race and period of
follow-up were collected. Main outcome measure was IOP at
ﬁnal visit. Statistical analyses included random effects pooled
estimates of treatment effects, tests for publication bias, and
random-effects models to obtain adjusted treatment effects on
ﬁnal IOP after controlling for baseline IOP, and duration of
follow-up. We also estimated the number of responders (IOP <
18 mmHg) based on mean IOP value, standard deviation, and
sample size. Random effects Poisson regression models were used
to estimate the adjusted effects of treatments on response rates.
RESULTS: A total of 224 papers were identiﬁed, including 15
randomized clinical trials. Nine studies were used in the analy-
sis. Patient age varied from 56.7 to 68.8 years and baseline IOP
ranged from 22.3 to 26.5 mmHg. At total of 378 patients 
were treated with bimatoprost, 385 with travoprost and 555
with latanoprost. Patients treated with travoprost and bimato-
prost tended to have similarly lower IOP levels at the end of
follow-up (−0.98 mmHg [95% CI: −2.08;0.13] and −1.04 mmHg
[95% CI: −2.11;0.04], respectively) than those treated with
latanoprost. The combined effect of newer prostaglandin ana-
logues (bimatoprost/travoprost) was an adjusted decrease of
1.00 mmHg [95% CI: −1.91;−0.10], or a 17% higher adjusted
response rate (Incidence Rate Ratio 1.17, 95% CI, 1.00–1.35, p
= 0.04), compared to latanoprost. CONCLUSION: Travoprost
and bimatoprost may have greater efﬁcacy in controlling IOP for
patients with OHT or glaucoma.
PEY4
EFFECTIVENESS OF BRIMONIDINE VERSUS BRINZOLAMIDE
IN TREATMENT OF GLAUCOMA: AN ANALYSIS CONDUCTED
ON THE UNITED-KINGDOM GENERAL PRACTITIONER
RESEARCH DATABASE
Berdeaux G1, Lafuma A2, Guelfucci F3
1Alcon France, Rueil-Malmaison, France, 2Cemka-Eval, Bourd-la-Reine,
France, 3Cemka-Eval, Bourg-la-Reine, France
OBJECTIVE: To compare the effectiveness of brinzolamide
(Azopt®) and brimonidine (Alphagan®) in the treatment of
glaucoma according to the data collected in the United-Kingdom
General Practitioner Research Database (UK-GPRD).
METHODS: Files with a diagnosis of ocular hypertension, or
glaucoma, or treated with a topical treatment surgery or laser
were extracted. Patients with prescription for brimonidine or
dorzolamide mono-therapy were selected regardless of treatment
line (initial, second line, third, etc.). Treatment failure was
deﬁned as a prescription change (adding or removing a topical
treatment). Time to treatment failure was compared using an
adjusted Cox model. Adjustment for confounding factors used
the propensity score method. RESULTS: A total of 56,612
patients were extracted and 39,808 patients had at least one
topical prescription for glaucoma. A total of 2175 were treated
with brimonidine and 482 with brinzolamide monotherapy. No
signiﬁcant difference in the characteristics of the patients was
found. Patients were 69.5 years old on average at diagnosis and
46.5% were male. At one year, 54.4% of the brimonidine
patients had a treatment failure versus 42.3% with brinzolamide
(P < 0.001). The hazard ratio for a failure was 0.798 (P < 0.001)
lower with brinzolamide, after adjusting for age, gender, and
comorbidities. CONCLUSION: According to the UK-GPRD
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information, brinzolamide is more efﬁcient than brimonidine in
the treatment of glaucoma patients, in mono-therapy, in all treat-
ment lines. Patients remained treated longer with brinzolamide.
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OBJECTIVE: To compare physician and patient rating of dry
eye disease severity over time, with standard clinical tests and a
QoL measure within a patient registry. METHODS: Patients
with moderate to severe dry eye disease, who were attending the
dry eye clinic at the Royal Victoria Inﬁrmary in Newcastle, UK,
and consented to participate in a patient registry, were recruited.
Patients were managed as in routine clinical practise. Patients
and physicians rated disease severity at baseline and over time
on a scale of 0–9 (0 Normal, 1–3 Mild, 4–6 Moderate, 7–9
Severe). In addition, a range of standard clinical tests for dry eye
and a validated, quality of life instrument (Ocular Surface
Disease Index—OSDI®) were completed. RESULTS: Data from
75 patients were analysed, 91% were white females and 84%
were postmenopausal. Fifty-nine percent of patients had at least
4 follow up visits (mean time approx. 16 months). At baseline,
46% of patients rated their dry eye disease as moderate and 43%
as severe, compared to 62% as moderate and 36% as severe by
the physician. From baseline to visit 4, the change in disease
severity by category was 38% improved, 41% same and 21%
deteriorated by the patient’s assessment. In comparison, by the
physician’s assessment, 49% of patients improved, 49% stayed
the same and 2% deteriorated. The patient’s rating of their
disease correlated well with the OSDI® (Spearman correlation
coefﬁcient; 0.53, p < 0.001). The physician’s rating of disease
status correlated well with 2 of the standard clinical tests for dry
eye (Oxford staining; 0.50, p < 0.001 and Tear Function Index;
0.43, p < 0.001). CONCLUSIONS: Patients tend to rate their
dry eye disease as more severe than the physician. It is impor-
tant to include patient-reported outcomes as part of the assess-
ment of dry eye disease severity and the management of patients.
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OBJECTIVE: To compare the rate of capsulotomy with Nd:Yag
laser following cataract surgery involving intra-ocular (IOL)
implantation with three square edge IOL’s (hydrophobic acrylic
single piece IOL: Acrysof SA60AT, Alcon, hydrophobic acrylic
multi-piece IOL: AR40E, AMO, and hydrophilic acrylic single
piece IOL: XL-Stabi, IOLTech) after three years follow-up.
METHODS: A retrospective review of patients with at least one
eye having been implanted with an IOL, aged 50 to 85 years at
the time of surgery, operated on for cataract in 2001 or 2002 in
10 French surgical centers. Centers were recruited if they had
implanted at least 2 of the studied types of IOL’s in order to study
center effect. Medical charts of patients meeting inclusion and
exclusion criteria were reviewed to collect information during
the three year period following cataract surgery to identify
patients who had posterior capsular opaciﬁcation (PCO) requir-
ing Nd:YAG laser post-operatively. Data on the type of IOL
implanted was extracted from the patients’ charts, as was the
date and outcome of the Nd:YAG laser intervention. Kaplan-
Meier survival curve analysis with time to Nd:YAG laser analy-
sis was performed on the data and adjusted in Cox models for
center effect due to possible differences in Nd:YAG practices.
RESULTS: A total of 777 cataract patients were included and
analyzed (n = 256 for SA60AT, n = 256 for AR40E, n = 265 for
XL-Stabi). The 3-year rates of cataract patients with the oper-
ated eye free of PCO requiring Nd:YAG laser treatment were
88.3% with SA60AT, 75% with AR40E and 49.1% with XL-
Stabi (p < 0.0001). Adjusted Cox model gave a risk-ratio (RR)
of 2.88 for AR40E (p < 0.0001) and a RR of 5.217 for XL-Stabi
(p < 0.0001) compared to SA60AT (reference). CONCLUSION:
Cataract patients receiving the Acrysof SA60AT IOL implant 
had the lowest rate of PCO requiring Nd:YAG laser treatment
post-operatively.
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OBJECTIVE: This study estimated the incremental costs of using
olopatadine (Opatanol) compared to branded cromoglycate
(Opticrom) and generic cromoglycate in the treatment of season
allergic conjunctivitis (SAC) in the UK. METHODS: A literature-
based decision model was constructed depicting the management
of SAC sufferers >=4 years of age over four months (a typical
allergy season). The model considers the decision by a GP to ini-
tially treat a patient with olopatadine (1 drop in affected eyes
twice daily), branded and generic cromoglycate (1 or 2 drops in
affected eyes 4 times daily). Whilst published studies demostrate
olopatadine’s greater symptom reduction compared to cromo-
glycate, there was no evidence of any signiﬁcant differences
between the two treatments in terms of days of treatment and
overall probability of being successfully treated. Therefore, for
the purposes of this analysis both drugs were assumed to be
equally effective. Consequently, a cost-minimisation analysis was
performed to identify the least costly alternative from the per-
spective of the UK’s National Health Service (NHS). RESULTS:
Starting treatment with olopatadine is expected to lead to a
health care cost of GBP 92 (95%CI:46–150) over four months
compared to GBP 109 (95% CI:65–166) with branded cromo-
glycate and GBP 95 (95% CI: 51–152)with generic cromogly-
cate. Consequently, use of olopatadine instead of branded or
generic cromoglycate is expected to lead to a 16% and 3%
reduction in health care costs respectively over four months of
treatment. This cost-difference is primarily due to fewer GP visits
among olopatadine-treated patients. CONCLUSIONS: Use of
olopatadine instead of branded or generic cromoglycate affords
an economic beneﬁt to the NHS. Hence, within the limitations
of our model, olopatadine is the preferred ﬁrst-line treatment for
use in SAC sufferers, since it is expected to release health care
resources for alternative use and may offer better symptom
reduction to patients.
